Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia
- 21 October 2004
- journal article
- research article
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 20 (12), 1979-1991
- https://doi.org/10.1185/174234304x15174
Abstract
Eszopiclone is a new, single-isomer, non-benzodiazepine, cyclopyrrolone agent under investigation for the treatment of insomnia. The present study was a randomized, double-blind, multicenter, placebo-controlled trial conducted to assess the efficacy and safety of eszopiclone in adults with chronic primary insomnia. Patients (n = 308) were randomized to receive placebo or eszopiclone (2 mg or 3 mg) for 44 consecutive nights, followed by 2 nights of single-blind placebo. Efficacy was evaluated with polysomnography (Nights 1, 15 and 29) and patient-reports (Nights 1, 15, 29 and 43/44). Next-day residual effects were evaluated using the Digit-Symbol Substitution Test (DSST). Eszopiclone 3 mg had significantly less time to sleep onset (p < or = 0.0001), more total sleep time and sleep efficiency (p < or = 0.0001), better sleep maintenance (p < or = 0.01), and enhanced quality and depth of sleep (p < 0.05) across the double-blind period compared with placebo. Eszopiclone 2 mg had significantly less time to sleep onset (p < or = 0.001), more total sleep time (p < or = 0.01) and sleep efficiency (p < or = 0.001), and enhanced quality and depth of sleep (p < 0.05) compared with placebo, but did not significantly improve sleep maintenance. There was no evidence of tolerance or rebound insomnia after therapy discontinuation. Median DSST scores showed no decrement in psychomotor performance relative to baseline and did not differ from placebo in either eszopiclone group. Treatment was well tolerated; the most common adverse event related to eszopiclone was unpleasant taste. Patients treated with nightly eszopiclone 3 mg had better polysomnographic (through Night 29) and patient-reported measures (through Night 44) of sleep over the 6-week trial. There was no evidence of tolerance or rebound insomnia and no detrimental effects on next-day psychomotor performance using the DSST.Keywords
This publication has 22 references indexed in Scilit:
- Epidemiology of insomnia: what we know and what we still need to learnSleep Medicine Reviews, 2002
- Continuous versus non-nightly use of zolpidem in chronic insomnia: results of a large-scale, double-blind, randomized, outpatient studyInternational Clinical Psychopharmacology, 2002
- Reported Chronic Insomnia Is Independent of Poor Sleep as Measured by ElectroencephalographyPsychosomatic Medicine, 2000
- Subjective hypnotic efficacy of trazodone and zolpidem in DSMIII-R primary insomniaHuman Psychopharmacology: Clinical and Experimental, 1998
- Minimal Rebound Insomnia After Treatment with 10-mg ZolpidemClinical Neuropharmacology, 1997
- Zolpidem, Triazolam, and TemazepamJournal of Clinical Psychopharmacology, 1996
- Estazolam and Flurazepam: A Multicenter, Placebo-Controlled Comparative Study in Outpatients with InsomniaThe Journal of Clinical Pharmacology, 1990
- Daytime Alertness in Patients with Chronic Insomnia Compared with Asymptomatic Control SubjectsSleep, 1988
- Insomnia and Its TreatmentArchives of General Psychiatry, 1985
- The effects of flurazepam, lorazepam, and triazolam on sleep and memoryPsychopharmacology, 1980